A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: An SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG

Annals of Oncology

Volumn 24, Issue 3, 2013, Pages 679-687

  Banerjee, S ^a   Rusti, G ^b   Paul, J ^c   Williams, C ^d   Pledge, S ^e   Gabra, H ^f   Skailes, G ^h   Lamont, A ^g   Hindley, A ^h   Goss, G ^k   Gilby, E ⁱ   Hogg, M ^h   Harper, P ^j   Kipps, E ^a   Lewsley, L A ^c   Hall, M ^b   Vasey, P ^l   Kaye, S B ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

^c BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^d UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^e WESTON PARK HOSPITAL   (United Kingdom)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g IPSWICH HOSPITAL NHS TRUST   (United Kingdom)

^h ROYAL PRESTON HOSPITAL   (United Kingdom)

ⁱ ROYAL UNITED HOSPITAL   (United Kingdom)

^j GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^k Epworth Eastern Hospital   (United Kingdom)

^l UNIVERSITY OF QUEENSLAND   (Australia)

more..

Author keywords

Carboplatin; Dose escalation; Myelosuppresssion; Ovarian cancer.

Indexed keywords

CARBOPLATIN;

ADVANCED CANCER; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER STAGING; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED STUDY; DRUG DOSE; DRUG DOSE ESCALATION; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLAT DOSE; HAZARD RATIO; HUMAN; INFECTION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OVARY CANCER; OVERALL SURVIVAL; PERITONEUM CANCER; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEPSIS; STOMATITIS; THROMBOCYTE COUNT; TREATMENT OUTCOME; UTERINE TUBE CARCINOMA; VOMITING;

EID: 84874560439     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds494     Document Type: Article

References (27)

1. du Bois A, Quinn M, Thigpen T et al.. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005; 16(Suppl 8): viii7-viii12.
2. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002; 360(9332): 505-515.
3. Calvert AH, Newell DR, Gumbrell LA et al.. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7(11): 1748-1756.
4. Di Maio M, Gridelli C, Gallo C et al.. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol 2005; 6(9): 669-677.
5. Horwich A, Sleijfer DT, Fossa SD et al.. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 1997; 15(5): 1844-1852.
6. Schmidt H, Suciu S, Punt CJ et al.. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. J Clin Oncol 2007; 25(12): 1562-1569.
7. Lee CK, Gurney H, Brown C et al.. Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. Br J Cancer 2011; 105(3): 360-365.
8. Rankin EM, Mill L, Kaye SB et al.. A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer. Br J Cancer 1992; 65(2): 275-281.
9. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975; 31(1): 103-115.
10. Ngan HY, Choo YC, Cheung M et al.. A randomized study of high-dose versus low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. Hong Kong Ovarian Carcinoma Study Group. Chemotherapy 1989; 35(3): 221-227.
11. Kaye SB, Paul J, Cassidy J et al.. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group. J Clin Oncol 1996; 14(7): 2113-2119.
12. Gurney H. How to calculate the dose of chemotherapy. Br J Cancer 2002; 86(8): 1297-1302.
13. Bergh J, Wiklund T, Erikstein B et al.. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet 2000; 356(9239): 1384-1391.
14. Vasey PA, Jayson GC, Gordon A et al.. Phase III randomized trial of docetaxelcarboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004; 96(22): 1682-1691.
15. Thavaramara T, Phaloprakarn C, Tangjitgamol S et al. Role of neutrophil to lymphocyte ratio as a prognostic indicator for epithelial ovarian cancer. J Med Assoc Thai 2011; 94(7): 871-877.
16. Aliustaoglu M, Bilici A, Seker M et al.. The association of pre-treatment peripheral blood markers with survival in patients with pancreatic cancer. Hepatogastroenterology 2010; 57(99-100): 640-645.
17. Cho H, Hur HW, Kim SW et al.. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 2009; 58(1): 15-23.
18. Michael M, Goldstein D, Clarke SJ et al.. Prognostic factors predictive of response and survival to a modified FOLFOX regimen: importance of an increased neutrophil count. Clin Colorectal Cancer 2006; 6(4): 297-304.
19. Stone RL, Nick AM, McNeish IA et al.. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012; 366(7): 610-618.
20. Rocconi RP, Matthews KS, Kemper MK et al.. Chemotherapy-related myelosuppression as a marker of survival in epithelial ovarian cancer patients. Gynecol Oncol 2008; 108(2): 336-341.
21. Shojaei F, Ferrara N. Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. Cancer Res 2008; 68(14): 5501-5504.
22. Shojaei F, Wu X, Qu X et al.. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci USA 2009; 106(16): 6742-6747.
23. Shojaei F, Wu X, Qu X et al.. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci USA 2009; 106(16): 6742-6747.
24. Heng DY, Xie W, Regan MM et al.. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27(34): 5794-5799.
25. Perren TJ, Swart AM, Pfisterer J et al.. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365(26): 2484-2496.
26. Burger RA, Brady MF, Bookman MA et al.. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365(26): 2473-2483.
27. Aghajanian C, Blank SV, Goff BA et al.. OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012; 30(17): 2039-2045.